Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;134(5):1255-1264.
doi: 10.1038/jid.2013.501. Epub 2013 Nov 25.

Vitamin D controls murine and human plasmacytoid dendritic cell function

Affiliations
Free article

Vitamin D controls murine and human plasmacytoid dendritic cell function

Nina Karthaus et al. J Invest Dermatol. 2014 May.
Free article

Abstract

Topical application of the vitamin D (VitD) analog calcipotriol is a highly effective standard treatment modality of psoriatic skin lesions. However, the immune modulatory effects of the treatment are incompletely understood. VitD is well known to induce tolerogenic responses in conventional dendritic cells (cDCs). Plasmacytoid DCs (pDCs) comprise a specialized, naturally occurring DC subset known to be important in autoimmune diseases including psoriasis. pDCs from the blood rapidly infiltrate psoriatic skin and are key to the initiation of the immune-mediated pathogenesis of the disease. We now demonstrate that pDCs express various proteins of the VitD receptor (VDR) pathway, including the VitD-metabolizing enzymes Cyp27B1 and Cyp24A1, and that VDR is transcriptionally active in pDCs. Moreover, VitD impairs the capacity of murine and human pDCs to induce T-cell proliferation and secretion of the T-helper 1 cytokine IFNγ. The inhibitory effect of VitD is dependent on the expression of the VDR in the DCs. This study demonstrates that VitD signaling can act as a natural inhibitory mechanism on both cDCs and pDCs, which may instigate the development of VitD-based therapeutic applications for psoriasis and other inflammatory skin diseases.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Blood. 2013 Jan 17;121(3):459-67 - PubMed
    1. FASEB J. 2012 Sep;26(9):3901-15 - PubMed
    1. Pharmacol Toxicol. 1995 Oct;77(4):241-6 - PubMed
    1. Skinmed. 2012 Nov-Dec;10(6):356-60 - PubMed
    1. J Pharmacol Exp Ther. 2008 Jan;324(1):23-33 - PubMed

Publication types

MeSH terms

LinkOut - more resources